Exanta (ximelagatran) won't be approved and won't be replacing warfarin any time soon

The new anticoagulant Exanta (ximelagatran) won't be approved and won't be replacing warfarin any time soon.

The problem is liver toxicity.

It was hoped that Exanta would be safer and easier to use.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote